Marshall Wace
KRSA

Marshall Wace’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Marshall Wace’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-75
Closed -$18K – 3463
2021
Q4 		$18K Buy
+75
New +$3.54K ﹤0.01% 3713
2021
Q3 		– Sell
-206
Closed -$113K – 3080
2021
Q2 		$113K Buy
+206
New +$12.9K ﹤0.01% 2529

Other funds holding KRSA

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Marshall Wace's KRSA Position: Q1 2022 in Review

Marshall Wace sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q1 2022, closing a stake of 75 shares — an estimated $18K sold.

Marshall Wace first reported a position in KRSA in Q2 2021 and held it in 2 quarters. The position peaked at $113K in Q2 2021. 46 funds tracked by Wall St. Rank hold KRSA as of Q1 2022.

  • Marshall Wace reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Marshall Wace sold 75 Korsana Biosciences, Inc. Common Stock shares in Q1 2022, an estimated $18K.
  • Marshall Wace first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Marshall Wace's Korsana Biosciences, Inc. Common Stock position peaked at $113K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.